Core Insights - The Franklin U.S. Equity Index ETF (USPX) is a smart beta ETF that debuted on June 1, 2016, providing broad exposure to the Style Box - All Cap Blend category of the market [1] - Smart beta ETFs track non-cap weighted strategies, appealing to investors who prefer selecting stocks based on fundamental characteristics to outperform the market [3] - The fund is sponsored by Franklin Templeton Investments and has assets exceeding $1.28 billion, targeting large and mid-cap U.S. stocks representing the top 85% of the U.S. equity market by float-adjusted market capitalization [5] Fund Details - The ETF has an annual operating expense ratio of 0.03%, making it one of the least expensive options in its category, with a 12-month trailing dividend yield of 1.16% [6] - The fund's largest sector allocation is in Information Technology, comprising approximately 33.3% of the portfolio, followed by Financials and Consumer Discretionary [7] - Microsoft Corp (MSFT) is the largest holding at about 6.74% of total assets, with the top 10 holdings accounting for approximately 34.89% of USPX's total assets [8] Performance Metrics - As of July 11, 2025, the ETF has gained about 7.63% year-to-date and 13.15% over the past year, with a trading range between $43.36 and $55.00 in the past 52 weeks [10] - The ETF has a beta of 0.90 and a standard deviation of 17.62% over the trailing three-year period, indicating effective diversification of company-specific risk with around 563 holdings [10] Alternatives - The Franklin U.S. Equity Index ETF is a viable option for investors looking to outperform the Style Box - All Cap Blend segment, but there are alternative ETFs such as iShares Core S&P Total U.S. Stock Market ETF (ITOT) and Vanguard Total Stock Market ETF (VTI) [11][12] - Both ITOT and VTI have significantly larger asset bases, with $72.02 billion and $506.04 billion respectively, and maintain an expense ratio of 0.03% [12]

Core Insights - The American Century U.S. Quality Value ETF (VALQ) debuted on January 11, 2018, and provides broad exposure to the Style Box - All Cap Value category of the market [1] - VALQ is managed by American Century Investments and aims to match the performance of the American Century U.S. Quality Value Index, focusing on undervalued large and mid-cap companies with sustainable income [5] Fund Characteristics - VALQ has accumulated over $251.3 million in assets, making it one of the larger ETFs in its category [5] - The fund has an annual operating expense ratio of 0.29%, which is competitive within its peer group, and a 12-month trailing dividend yield of 1.73% [6] - The fund's portfolio is heavily allocated to the Information Technology sector, which represents 26% of its holdings, followed by Healthcare and Consumer Staples [7] Holdings and Performance - Cisco Systems Inc (CSCO) is the largest individual holding at approximately 2.81% of total assets, with the top 10 holdings accounting for about 25.2% of VALQ's total assets [8] - Year-to-date, VALQ has increased by 4.56% and has risen by 12.57% over the last 12 months as of July 11, 2025, with a trading range between $54.09 and $64.64 in the past 52 weeks [10] - The fund has a beta of 0.87 and a standard deviation of 14.59% over the trailing three-year period, indicating effective diversification of company-specific risk with approximately 231 holdings [10] Alternatives - While VALQ is a viable option for investors looking to outperform the Style Box - All Cap Value segment, there are alternative ETFs such as Fidelity High Dividend ETF (FDVV) and iShares Core S&P U.S. Value ETF (IUSV) that may offer lower expense ratios and different risk profiles [11][12]

Core Viewpoint - The Pacer US Small Cap Cash Cows ETF (CALF) is a smart beta ETF that targets small-cap value stocks with high free cash flow yields, aiming to outperform traditional market cap weighted indexes [1][5]. Fund Overview - CALF was launched on June 16, 2017, and has accumulated over $4.32 billion in assets, positioning it as one of the larger ETFs in the small-cap value category [1][5]. - The ETF seeks to match the performance of the Pacer US Small Cap Cash Cows Index, which employs a rules-based methodology [5]. Cost Structure - The annual operating expenses for CALF are 0.59%, which is relatively high compared to other products in the space [6]. - The fund has a 12-month trailing dividend yield of 1.04% [6]. Sector Exposure and Holdings - The ETF has a significant allocation in the Industrials sector, comprising approximately 21.9% of the portfolio, followed by Consumer Discretionary and Information Technology [7]. - The top holding, Cf Industries Holdings Inc, accounts for about 2.31% of total assets, with the top 10 holdings representing around 20.38% of CALF's total assets [8]. Performance Metrics - As of July 11, 2025, CALF has experienced a year-to-date loss of approximately -4.85% and a decline of about -0.79% over the past year [10]. - The ETF has traded between $32.00 and $48.76 in the past 52 weeks, with a beta of 1.09 and a standard deviation of 23.22% over the trailing three-year period [10]. Alternatives - Other ETFs in the small-cap value space include iShares Russell 2000 Value ETF (IWN) and Vanguard Small-Cap Value ETF (VBR), which have lower expense ratios and larger asset bases [12].

Core Insights - The First Trust Growth Strength ETF (FTGS) was launched on October 25, 2022, and offers broad exposure to the Style Box - Large Cap Growth category of the market [1] Fund Overview - FTGS is managed by First Trust Advisors and has accumulated over $1.16 billion in assets, positioning it as an average-sized ETF in its category [5] - The ETF aims to match the performance of the Growth Strength Index, which focuses on domestic equities filtered for liquidity, return on equity, long-term debt, revenue, and cash flow growth [5] Cost Structure - FTGS has annual operating expenses of 0.60%, making it one of the more expensive options in the smart beta ETF space [6] - The ETF has a 12-month trailing dividend yield of 0.33% [6] Sector Exposure and Holdings - The Information Technology sector represents the largest allocation at 30.7%, followed by Financials and Industrials [7] - Vertiv Holdings Co (VRT) constitutes about 2.62% of total assets, with the top 10 holdings accounting for approximately 24.08% of FTGS's total assets [8] Performance Metrics - As of July 10, 2025, FTGS has gained roughly 10.5% year-to-date and 12.94% over the past year [10] - The ETF has traded between $26.62 and $34.67 in the last 52 weeks, with a beta of 1.13 and a standard deviation of 17.98% over the trailing three-year period [10] Alternatives - Other ETFs in the large-cap growth space include Vanguard Growth ETF (VUG) with $176.96 billion in assets and an expense ratio of 0.04%, and Invesco QQQ (QQQ) with $356.12 billion in assets and an expense ratio of 0.20% [11]

Core Viewpoint - The Invesco Pharmaceuticals ETF (PJP) is a smart beta ETF designed to provide broad exposure to the healthcare sector, specifically focusing on U.S. pharmaceutical companies [1][5][6]. Fund Overview - PJP was launched on June 23, 2005, and has accumulated over $239.95 million in assets, categorizing it as an average-sized ETF within the healthcare sector [1][5]. - The fund aims to match the performance of the Dynamic Pharmaceutical Intellidex Index, which evaluates companies based on various investment merit criteria [5][6]. Cost and Expenses - PJP has an annual operating expense ratio of 0.56%, which is competitive with most peer products in the healthcare ETF space [7]. - The fund offers a 12-month trailing dividend yield of 1.16% [7]. Sector Exposure and Holdings - The ETF is fully allocated to the healthcare sector, with approximately 100% of its portfolio dedicated to this area [8]. - Eli Lilly & Co (LLY) constitutes about 5.41% of the fund's total assets, followed by Amgen Inc (AMGN) and Pfizer Inc (PFE). The top 10 holdings represent approximately 46.64% of total assets [9]. Performance Metrics - As of July 10, 2025, PJP has gained roughly 0.8% year-to-date and approximately 2.82% over the past year [11]. - The fund has traded between $74.59 and $89.61 in the last 52 weeks, with a beta of 0.47 and a standard deviation of 15.71% over the trailing three-year period, indicating a higher risk profile compared to peers [11]. Alternatives - Other ETFs in the pharmaceutical space include iShares U.S. Pharmaceuticals ETF (IHE) and VanEck Pharmaceutical ETF (PPH), which have lower expense ratios of 0.39% and 0.36%, respectively [13]. - Investors seeking lower-risk options may consider traditional market cap weighted ETFs that aim to match healthcare sector returns [13].

Core Viewpoint - The First Trust Rising Dividend Achievers ETF (RDVY) is a smart beta ETF that aims to provide broad exposure to the large-cap value segment of the market, focusing on companies with a history of paying dividends [1][5]. Fund Overview - RDVY was launched on January 7, 2014, and has accumulated over $15.23 billion in assets, making it one of the larger ETFs in its category [1][5]. - The fund is managed by First Trust Advisors and seeks to match the performance of the NASDAQ US Rising Dividend Achievers Index [5]. Cost and Performance - The ETF has an annual operating expense ratio of 0.48%, which is competitive within its peer group [6]. - It offers a 12-month trailing dividend yield of 1.43% [6]. - The ETF has returned approximately 8.19% and is up about 18.06% year-to-date as of July 10, 2025 [9]. Sector Exposure and Holdings - RDVY's largest sector allocation is in Financials, comprising approximately 38.6% of the portfolio, followed by Information Technology and Consumer Discretionary [7]. - Ebay Inc. (EBAY) represents about 2.52% of the fund's total assets, with the top 10 holdings accounting for around 23.33% of total assets under management [8]. Risk Profile - The ETF has a beta of 1.07 and a standard deviation of 19.07% over the trailing three-year period, indicating a medium risk profile [9]. - With approximately 77 holdings, RDVY effectively diversifies company-specific risk [9]. Alternatives - Other ETFs in the large-cap value space include Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Value ETF (VTV), which have significantly larger asset bases and lower expense ratios [11].

Core Insights - The SPDR S&P Biotech ETF (XBI) is a smart beta ETF launched on January 31, 2006, providing broad exposure to the Health Care ETFs category [1] - XBI is managed by State Street Global Advisors and has over $5.04 billion in assets, making it one of the largest ETFs in the Health Care sector [5] - The ETF aims to match the performance of the S&P Biotechnology Select Industry Index, which is a modified equal weight index representing the biotechnology sub-industry [6] Investment Strategy - Smart beta ETFs like XBI focus on non-cap weighted strategies, selecting stocks based on fundamental characteristics to enhance risk-return performance [3] - The ETF has an annual operating expense ratio of 0.35%, making it one of the least expensive options in its category [7] Sector Exposure and Holdings - XBI's portfolio is entirely allocated to the Healthcare sector, with Insmed Inc (INSM) being the largest holding at approximately 3.29% of total assets [8][9] - The top 10 holdings of XBI account for about 27.56% of its total assets under management [9] Performance Metrics - Year-to-date, XBI has experienced a loss of approximately -2.42%, and over the last 12 months, it is down about -6.86% [11] - The ETF has a beta of 0.86 and a standard deviation of 29.73% over the trailing three-year period, indicating a higher risk profile [11] Alternatives - Other ETFs in the biotechnology space include the First Trust NYSE Arca Biotechnology ETF (FBT) and the iShares Biotechnology ETF (IBB), with assets of $1.03 billion and $5.52 billion respectively [13] - FBT has an expense ratio of 0.54%, while IBB charges 0.45%, providing investors with alternative options [13]

Core Insights - The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) is a smart beta ETF launched on October 9, 2013, providing exposure to the Large Cap Value category [1] - NOBL has accumulated over $11.6 billion in assets, making it one of the larger ETFs in its category [5] - The ETF aims to match the performance of the S&P 500 Dividend Aristocrats Index, which includes companies that have increased dividend payments for at least 25 consecutive years [5] Fund Characteristics - NOBL has an annual operating expense ratio of 0.35%, which is competitive within its peer group [6] - The ETF's 12-month trailing dividend yield is 2.07% [6] - The fund has a beta of 0.84 and a standard deviation of 14.52% over the trailing three-year period, indicating medium risk [10] Sector Exposure and Holdings - The ETF has a significant allocation in the Industrials sector, comprising approximately 23.5% of the portfolio, followed by Consumer Staples and Financials [7] - Emerson Electric Co (EMR) is the largest individual holding at about 1.79% of total assets, with the top 10 holdings accounting for approximately 14.94% of total assets [8] Performance - NOBL has experienced a year-to-date increase of about 10.3% and a total increase of roughly 4.3% [10] - The ETF has traded within a range of $90.85 to $108.47 over the past 52 weeks [10] Alternatives - Other ETFs in the same space include iShares Core Dividend Growth ETF (DGRO) and Vanguard Dividend Appreciation ETF (VIG), with assets of $32.43 billion and $93.11 billion respectively [12] - DGRO has a lower expense ratio of 0.08%, while VIG has an expense ratio of 0.05% [12]

Group 1 - The core viewpoint of the article highlights the rapid growth and increasing popularity of ETFs (Exchange-Traded Funds) among investors due to their convenience, low fees, and stable investment styles [1] - Major securities firms are seizing the opportunities presented by the expanding ETF market, with leading firms like Huatai Securities dominating various segments of the ETF business [1][2] - As of the end of May, the total number of ETFs in the Shanghai market reached 691, with a total market value of 3 trillion yuan, while the Shenzhen market had 483 ETFs valued at 1.1 trillion yuan [2] Group 2 - In May, the top three securities firms by ETF trading volume on the Shanghai Stock Exchange were Huatai Securities, CITIC Securities, and Guotai Junan, with market shares of 11.3%, 9.35%, and 7.48% respectively [2] - By the end of May, China Galaxy Securities led in ETF holdings with a market share of 24.63%, followed by Shenwan Hongyuan Securities at 18.05% [3] - The trading account numbers for ETFs in May showed that Huatai Securities and East Money Securities each held over 10% of the market share in the Shanghai market [4] Group 3 - The ETF market has shown strong growth, with the total number of ETFs reaching 1,207 by June 29, a year-on-year increase of 24.05%, and total net assets growing by 73.03% to 4.28 trillion yuan [5] - Analysts predict that the Chinese ETF market is entering a historic expansion phase, with a focus on broad-based ETFs and thematic ETFs in sectors like technology and finance [5] - Securities firms are enhancing their ETF strategies to capture growth opportunities, with firms like China Merchants Securities focusing on the entire ETF value chain and Guohai Securities optimizing their product offerings [5][6]

Group 1 - The article highlights the rebound of high dividend assets, with the Cash Flow ETF (159399) rising by 0.89% during trading, indicating active market participation [1] - The Cash Flow ETF (159399) utilizes free cash flow as a stock selection factor, closely tracking the FTSE China A-Share Free Cash Flow Focus Index, excluding financial and real estate sectors, and selecting the top 50 stocks with the highest free cash flow rates, thus identifying "cash cow" companies in the A-share market [1] - The long-term performance of the FTSE Cash Flow Index is notable, with an annualized return exceeding 18% since the base date (December 31, 2013), and a cumulative increase of 568.15%, significantly outperforming the CSI 300's 114.88% and the CSI Dividend's 285.62%, consistently beating the CSI Dividend Index for nine consecutive years [1] Group 2 - According to Shenwan Hongyuan Securities, free cash flow has a timing effect on cyclical stocks, suggesting that during an upcycle, the free cash flow rate of cyclical stocks is higher compared to recession periods, allowing for the identification of cyclical stocks in an uptrend through free cash flow rates, demonstrating strong applicability to economic cycles [1]